Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,367.12 370.31 2.65%
TOPIX 1,162.60 26.51 2.33%
HANG SENG 22,834.05 162.79 0.72%

AMRN SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter LLP Is Investigating Amarin Corporation plc.



  AMRN SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter LLP Is Investigating
  Amarin Corporation plc.

Business Wire

NEW YORK -- October 13, 2013

The law firm of Wohl & Fruchter LLP is investigating possible violations of
federal securities laws by officers and directors of Amarin Corporation plc
(Amarin) (NASDAQ: AMRN).

On October 11, 2013, the Food & Drug Administration (FDA) released its
briefing documents for the scheduled October 16, 2013 advisory committee
review of Amarin’s application seeking expanded approval for the use of its
fish oil-based drug, Vascepa, in the treatment of adult patients with high
triglycerides with mixed dyslipidemia.

The FDA briefing documents raised questions about the mineral oil placebo used
in the ANCHOR clinical trial intended to support the expanded approval,
thereby potentially negatively impacting the control group data, and
suggesting that “the treatment effects observed with [Vascepa] may be
overestimated.”

The FDA briefing documents also suggested it may be prudent to await the
results of the REDUCE-IT trial being conducted by Amarin to evaluate the
effectiveness of Vascepa in reducing cardiovascular events (which will only be
completed in approximately six years) before approving expansion of the
treatment indication for Vascepa.

On the above news, AMRN shares declined over 20%.

Wohl & Fruchter’s investigation concerns whether Amarin management misled
investors concerning, among other things, potential flaws in the design of the
ANCHOR clinical trial, and the potential relevance of data from the ongoing
REDUCE-IT trial to approval of the expanded indication for Vascepa.

Persons with relevant information, and AMRN shareholders with questions about
this investigation, are invited to contact the attorney below, or our Firm by
calling 866.833.6245.

Additional information, including a copy of the FDA briefing documents
referenced above, is available on our website at:
http://www.wohlfruchter.com/cases/amrn.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and
other fiduciary breaches by corporate managers, as well as other complex
litigation matters. Please visit our website, www.wohlfruchter.com, to learn
more about our Firm and its successes, or to contact one of our partners.

This release may be deemed to constitute attorney advertising.

Contact:

Wohl & Fruchter LLP
J. Elazar Fruchter
845-425-4658 or Toll Free 866-833-6245
jfruchter@wohlfruchter.com
www.wohlfruchter.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement